Stockreport

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome [Yahoo! Finance]

Rhythm Pharmaceuticals, Inc.  (RYTM) 
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am Check Earnings Report
US:NASDAQ Investor Relations: ir.rhythmtx.com
PDF -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS -- -- Company initiated Phase 1, Part D study to evaluate weekly MC4R agonist [Read more]